227 related articles for article (PubMed ID: 24383114)
1. Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma.
Kunstman JW; Korah R; Healy JM; Prasad M; Carling T
Surgery; 2013 Dec; 154(6):1255-61; discussion 1261-2. PubMed ID: 24383114
[TBL] [Abstract][Full Text] [Related]
2. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
3. BRAF mutation and RASSF1A expression in thyroid carcinoma of southern Italy.
Santoro A; Pannone G; Carosi MA; Francesconi A; Pescarmona E; Russo GM; Feola A; Losito S; Franco R; Nappi L; Aquino G; De Rosa G; Di Domenico M; Bufo P
J Cell Biochem; 2013 May; 114(5):1174-82. PubMed ID: 23192464
[TBL] [Abstract][Full Text] [Related]
4. Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer.
Lin CI; Du J; Shen WT; Whang EE; Donner DB; Griff N; He F; Moore FD; Clark OH; Ruan DT
J Clin Endocrinol Metab; 2011 Mar; 96(3):E554-65. PubMed ID: 21190978
[TBL] [Abstract][Full Text] [Related]
5. Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARĪ²2 genes in papillary thyroid carcinoma.
Mohammadi-asl J; Larijani B; Khorgami Z; Tavangar SM; Haghpanah V; Kheirollahi M; Mehdipour P
Med Oncol; 2011 Dec; 28(4):1123-8. PubMed ID: 20535589
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological roles of alterations of tumor suppressor gene p16 in papillary thyroid carcinoma.
Lam AK; Lo CY; Leung P; Lang BH; Chan WF; Luk JM
Ann Surg Oncol; 2007 May; 14(5):1772-9. PubMed ID: 17195959
[TBL] [Abstract][Full Text] [Related]
7. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
8. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
9. DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma.
Yin DT; Wu W; Li M; Wang QE; Li H; Wang Y; Tang Y; Xing M
Endocr Relat Cancer; 2013 Aug; 20(4):507-14. PubMed ID: 23702469
[TBL] [Abstract][Full Text] [Related]
10. [Aberrant methylation of hMLH1 gene promoter in papillary thyroid cancer and its clinical significance].
Lu XX; Ge MH; Ling ZQ; Hu SS; Xu J; Zheng CM; Tan Z; Chen C
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):833-6. PubMed ID: 24447481
[TBL] [Abstract][Full Text] [Related]
11. [Relationship between methylation status of promoter and expression of XAF1 gene in papillary thyroid carcinoma].
Yin DT; Chen G; Li HQ; Zheng XY; Wang YF; Zhang Y; Jiang JH; Wang QD
Zhonghua Yi Xue Za Zhi; 2012 Jul; 92(28):1967-70. PubMed ID: 22944270
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic regulation of Wnt signaling pathway gene SRY-related HMG-box 17 in papillary thyroid carcinoma.
Li JY; Han C; Zheng LL; Guo MZ
Chin Med J (Engl); 2012 Oct; 125(19):3526-31. PubMed ID: 23044318
[TBL] [Abstract][Full Text] [Related]
13. RASSF10 is Epigenetically Inactivated and Suppresses Cell Proliferation and Induces Cell Apoptosis by Activating the p53 Signalling Pathway in Papillary Thyroid Carcinoma Cancer.
Fan C; Wang W; Jin J; Yu Z; Xin X
Cell Physiol Biochem; 2017; 41(3):1229-1239. PubMed ID: 28268222
[TBL] [Abstract][Full Text] [Related]
14. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.
Hu S; Liu D; Tufano RP; Carson KA; Rosenbaum E; Cohen Y; Holt EH; Kiseljak-Vassiliades K; Rhoden KJ; Tolaney S; Condouris S; Tallini G; Westra WH; Umbricht CB; Zeiger MA; Califano JA; Vasko V; Xing M
Int J Cancer; 2006 Nov; 119(10):2322-9. PubMed ID: 16858683
[TBL] [Abstract][Full Text] [Related]
15. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
[TBL] [Abstract][Full Text] [Related]
16. Patterns of FOXE1 expression in papillary thyroid carcinoma by immunohistochemistry.
Bychkov A; Saenko V; Nakashima M; Mitsutake N; Rogounovitch T; Nikitski A; Orim F; Yamashita S
Thyroid; 2013 Jul; 23(7):817-28. PubMed ID: 23327367
[TBL] [Abstract][Full Text] [Related]
17. Methylation status of genes in papillary thyroid carcinoma.
Smith JA; Fan CY; Zou C; Bodenner D; Kokoska MS
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1006-11. PubMed ID: 17938324
[TBL] [Abstract][Full Text] [Related]
18. Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma.
Ferrario C; Lavagni P; Gariboldi M; Miranda C; Losa M; Cleris L; Formelli F; Pilotti S; Pierotti MA; Greco A
Lab Invest; 2008 May; 88(5):474-81. PubMed ID: 18332874
[TBL] [Abstract][Full Text] [Related]
19. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
[TBL] [Abstract][Full Text] [Related]
20. Methylation of p16 CpG islands correlated with metastasis and aggressiveness in papillary thyroid carcinoma.
Wang P; Pei R; Lu Z; Rao X; Liu B
J Chin Med Assoc; 2013 Mar; 76(3):135-9. PubMed ID: 23497965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
